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Abstract
Phosphodiesterase 10A (PDE10A) inhibitors show therapeutic effects for diseases with striatal pathology. PET radiotracers have been developed to quantify
in vivo PDE10A levels and target engagement for therapeutic interventions. The
aim of this study was to compare two potent and selective PDE10A radiotracers, [11C]TZ1964B and [18F]MNI659 in the nonhuman primate (NHP) brain.
Double scans in the same cynomolgus monkey on the same day were performed after injection of [11C]TZ1964B and [18F]MNI659. Specific uptake was
determined in two ways: nondisplaceable binding potential (BPND) was calculated using cerebellum as the reference region and the PDE-10A enriched striatum as the target region of interest (ROI); the area under the time–activity
curve (AUC) for the striatum to cerebellum ratio was also calculated. High-performance liquid chromatography (HPLC) analysis of solvent-extracted NHP
plasma identified the percentage of intact tracer versus radiolabeled metabolites
samples post injection of each radiotracer. Both radiotracers showed high specific accumulation in NHP striatum. [11C]TZ1964B has higher striatal retention
and lower specific striatal uptake than [18F]MNI659. The BPND estimates of
[11C]TZ1964B were 3.72 by Logan Reference model (LoganREF) and 4.39 by
simplified reference tissue model (SRTM); the BPND estimates for [18F]MNI659
were 5.08 (LoganREF) and 5.33 (SRTM). AUC ratios were 5.87 for [11C]
TZ1964B and 7.60 for [18F]MNI659. Based on BPND values in NHP striatum,
coefficients of variation were ~10% for [11C]TZ1964B and ~30% for [18F]
MNI659. Moreover, the metabolism study showed the percentage of parent
compounds were ~70% for [11C]TZ1964B and ~50% for [18F]MNI659 60 min
post injection. These data indicate that either [11C]TZ1964B or [18F]MNI659
could serve as suitable PDE10A PET radiotracers with distinguishing features
for particular clinical application.
Abbreviations
[11C]TZ1964B, 3-[11C]methoxy-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)
phenoxy)methyl)-quinoline; [18F]MNI659, 2-(2-(3-(4-(2-[18F]fluoroethoxy)phenyl)7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione;
AIR, Automated Image Registration; AUC, area under the time-activity curve; BPND,
binding potential (nondisplaceable); CNS, central nervous system; CV, coefficient of
variation; DARPP-32, dopamine and CAMP-regulated neuronal phosphoprotein 32;
DMSO, methyl sulfoxide; DVR, distribution volume ratio; FWHM, full width at half
maximum; HPLC, high-performance liquid chromatography; LoganREF, Logan
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Reference model; MP-RAGE, magnetization-prepared rapid gradient echo; NHP,
nonhuman primate; p.i., post injection; PDE10A, phosphodiesterase 10A; PET, positron emission tomography; PKA, protein kinase A; ROI, region of interest; SRTM,
simplified reference tissue model; SUV, standardized uptake value.

Introduction
Phosphodiesterase 10A (PDE10A) is a dual substrate
enzyme that hydrolyses cyclic adenosine monophosphate
(cAMP) and cyclic guanosine monophosphate (cGMP);
its distribution is exclusively within striatal medium spiny
neurons which are enriched in the striatum (Fujishige
et al. 1999; Coskran et al. 2006). PDE10A regulates
cAMP/cGMP downstream signaling cascades (e.g., cAMP/
protein kinase A(PKA)/dopamine and CAMP-regulated
neuronal phosphoprotein 32 (DARPP-32)) that influence
various neural functions including ion conductance and
synaptic plasticity and plays a key role in regulating
dopaminergic signaling in both direct and indirect striatal
pathways (Nishi et al. 2008; Girault 2012). Consequently,
enhancement of cAMP signaling through PDE10A knockout or PDE10A inhibition has been shown to affect locomotor activity and acquisition of conditioned avoidance
in rodent studies (Siuciak et al. 2006; Hebb et al. 2008;
Schmidt et al. 2008). Moreover, decreased PDE10A
expression has been observed both in animal models and
in patients with striatal pathologies, including Huntington
disease (HD) and Parkinson disease (PD) (Hebb et al.
2004; Giorgi et al. 2011; Russell et al. 2014; Niccolini
et al. 2015). These observations provided the rationale for
exploring PDE10A inhibition as a therapy for neuropsychiatric and neurodegenerative diseases. Following
promising therapeutic advances, tremendous efforts have
been put into the development of a suitable radioligand
for PDE10A positron emission tomography (PET) imaging. A potent and specific PDE10A PET radiotracer would
allow in vivo quantification of PDE10A levels in the brain
in a diverse array of central nervous system (CNS) diseases, and also could provide a metric for target engagement during therapeutic interventions. Several PDE10A
radioligands have been recently reported for preclinical or
clinical studies (Barret et al. 2014; Fan et al. 2014; Kehler
et al. 2014; Plisson et al. 2014; Russell et al. 2014; Hostetler et al. 2015; Li et al. 2015; Liu et al. 2015; Niccolini
et al. 2015). Although each ligand has its own set of
advantages and disadvantages, a close comparison of these
PDE10A radioligands could provide detailed information
for choosing the appropriate radiotracer for particular
clinical application.
In this paper, we have focused on a comparison of two
promising radioligands for PDE10A, [11C]TZ1964B and
[18F]MNI659, shown in Figure 1. TZ1964B shows high
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binding potency and good selectivity toward PDE10A,
with a IC50 value of 0.40  0.02 nmol/L (Li et al. 2013a).
Rat biodistribution and autoradiography studies revealed
that [11C]TZ1964B had high accumulation in the striatal
region and rapid clearance from non-target brain regions
(Fan et al. 2014; Liu et al. 2015), which was further confirmed by microPET studies in NHPs (Fan et al. 2014;
Liu et al. 2015). In comparison, MNI659 has subnanomolar binding potency for PDE10A (0.097 nM) (Barret et al.
2014). The reported regional brain uptake of [18F]
MNI659 in NHPs is consistent with PDE10A distribution:
highest in striatal regions and lowest in cerebellum (Barret et al. 2012). [18F]MNI659 has also been evaluated for
human brain imaging (Barret et al. 2014). TZ1964B and
MNI659 have similar lipophilicity and potent in vitro
binding affinity for PDE10A, but the radiotracers differ in
terms of in vivo kinetics. This study provides a head-tohead comparison of [11C]TZ1964B and [18F]MNI659 for
in vivo imaging of the NHP brain by collecting double
scans in a same subject in the same day.

Materials and Methods
Radioligand preparation
Radiosynthesis of [11C]TZ1964B. The synthesis of the
cold standard and precursor and radiosynthesis of [11C]
TZ1964B were accomplished following our published
procedures (Fig. 2) (Li et al. 2013a; Fan et al. 2014).
Radiosynthesis of [18F]MNI659. The radiosynthesis was
accomplished following published procedure with modification (Fig. 2) (Barret et al. 2014). Briefly, [18F]fluoride
was produced in our institution by 18O(p, n)18F reaction
through proton irradiation of enriched 18O water (95%)
using a RDS111 cyclotron (Siemens/CTI Molecular Imaging, Knoxville, TN). A bolus of aqueous [18F]fluoride
(~ 200 mCi) was added to a reaction vessel (13 mm 9
8 mm) containing Kryptofix 222 (6–8 mg) and aqueous
potassium carbonate solution (12.5 lL, 20 mg/mL). The
syringe was rinsed with ethanol twice (2 9 0.4 mL). The
resulting solution was evaporated under gentle nitrogen
flow in an oil bath that was preheated to 90°C. Acetonitrile
(3 9 1 mL) was added to the residue and trace amounts
of water was azeotropically removed by evaporation. A
solution of the tosylate precursor, 2-(4-(2-(2-(4-isopropoxy-1,3-dioxoisoindolin-2-yl)ethyl)-7-methyl-4-oxoquinazolin-3(4H)-yl)phenoxy)ethyl 4-methyl-benzenesulfonate
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Figure 1. Chemical structures of [11C]TZ1964B and [18F]MNI659.

Figure 2. Radiosynthesis Schemes of [11C]TZ1964B and [18F]MNI659.

(3–4 mg, MNI660, provided by Molecular Neuroimaging.
Inc, New Haven, CT) in DMSO (250 lL) was added to
the 18F-containing reaction vessel. The reaction vessel was
capped and swirled with a vortex, and then heated in an
oil bath at 90°C for 10 min. The reaction mixture was

diluted with 3.0 mL high-performance liquid chromatography (HPLC) mobile phase (acetonitrile/0.1 mol/L
ammonium formate buffer, pH 4.5, 60/40, v/v) and
passed through an alumina Neutral Sep-Pak Plus cartridge, and then loaded onto a HPLC system, which
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consisted of an Agilent SB-C18 semi-preparative HPLC
column (250 mm 9 9.6 mm) and UV detection at
254 nm, with a flow rate of 4 mL/min. Under these conditions, the retention time of [18F]MNI659 was 16–
18 min and the retention time of the precursor was 23–
24 min. The product [18F]MNI659 was collected into a
100 mL vial containing 50 mL sterile water and then
passed through a C-18 Sep-Pak Plus cartridge. [18F]
MNI659 was trapped on the Sep-Pak, then rinsed with
20 mL sterile water, the product [18F]MIN659 was eluted
into a sterile dose vial using USP grade 10% of ethanol
saline solution (6.0 mL). The final dose was delivered for
animal studies and quality control (QC) analysis. An aliquot (100 lL) was authenticated by co-injection with
nonradiolabeled standard reference MIN659 on an analytical HPLC system (Agilent SB-C18, 250 9 4.6 mm, 5 l)
with a mobile phase of acetonitrile/0.1 mol/L ammonium
formate buffer (75/25, v/v, pH~4.5). Under these conditions, the retention time for [18F]MNI659 was ~ 4.6 min
at a flow rate of 1.2 mL/min. The whole procedure took
about 70 min.

In vivo microPET studies in NHPs
Subjects
All animal experiments were conducted in compliance
with the Guidelines for the Care and Use of Research
Animals under protocols approved by Washington
University’s Animal Studies Committee. This work was
conducted at the Washington University School of Medicine in St. Louis. Animals were maintained in AAALACaccredited housing facilities with access to food and water
ad libitum, and 12-h dark and light cycles; all animals
were equally engaged with an enriched environment such
as watching movies or playing with appropriate toys.
PET imaging studies were carried out on two adult
male cynomolgus monkeys, weighing on 7–8 kg. Subject
A underwent three sets of double scans, and Subject B
underwent one set of double scans. Animals were prepared for microPET studies as previously reported (Liu
et al. 2015). About 1.5–2.5% isoflurane inhalation anesthesia was maintained throughout the microPET imaging
sessions. A 20-gage plastic catheter was inserted into a
limb vein to permit hydration and injection of the radiotracer. Arterial blood was collected through another 20gage plastic catheter which was placed into a femoral
artery.
PET data acquisition
The imaging studies of [11C]TZ1964B and [18F]MNI659
in the NHP brain through double scans were done using
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a MicroPET Focus 220 scanner (Concorde/CTI/Siemens
Microsystems, Knoxville, TN). For all the double scans,
[11C]TZ1964B studies were performed in the morning
and [18F]MNI659 in the afternoon, with an interval of
~3 h between the injection of each tracer. Prior to each
PET acquisition, a 45-min transmission scan for attenuation correction was performed following a 10 min transmission that was used to check the position of the brain
within the scanner. Subsequently, 296–370 MBq of [11C]
TZ1964B or [18F]MNI659 was intravenously injected, and
a 120 min dynamic (3 9 1-min frames, 4 9 2-min
frames, 3 9 3-min frames, and 20 9 5-min frames) PET
scan was acquired.
PET image processing
The PET images were processed according to the previous
report (Liu et al. 2015). Briefly, emission scans were corrected and reconstructed using filtered back projection as
described previously (Miller et al. 1989). The final reconstructed resolution was 2.00 mm full width at half maximum (FWHM) for all three dimensions (axial) at center
of the field of view. The actual field of view is 25.8 cm
diameter and a 7.6 cm axial length. The reconstructed
PET images was co-registered with magnetization-prepared rapid gradient echo (MP-RAGE) MR images using
Automated Image Registration (AIR) (Woods et al.
1993), and superimposed using Analyze 10.0 (AnalyzeDirect, Overland Park, KS) for quality control. For
quantitative analyses, three-dimensional regions of interest
(ROIs) for cerebellum (Subject A: 583 voxels; Subject B:
750 voxels, the voxel size is 1.858 mm 9 1.858 mm 9
0.796 mm = 2.75 lL), striatum (A: 695 voxels; B: 1158
voxels), frontal cortex (A: 263 voxels; B: 225 voxels), midbrain (A: 64 voxels; B: 118 voxels), and hippocampus (A:
68 voxels; B: 64 voxels) were identified on MRI images
and then transformed into PET images using the co-registration transformation matrix. The ROIs for each animal
were kept fixed for all subsequent studies once identified
on a baseline scan. Time–activity curves (TACs) for each
ROI were then obtained from the dynamic PET images.
Standardized uptake value (SUV) of each tracer was calculated and standardized to the body weight and the
injected dose of radioactivity.
Reference-based tracer kinetic analysis
Regional tracer uptake was quantified using two different
reference-based kinetic methods: Logan Reference (LoganREF) model (Logan et al. 1990, 1996; Innis et al. 2007;
Liu et al. 2015) and simplified reference tissue model
(SRTM) (Lammertsma and Hume 1996; Gunn et al.
1997; Innis et al. 2007; Liu et al. 2015). According to the
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LoganREF model, the distribution volume ratio (DVR) of
each ROI was calculated using a MATLAB (Mathworks
Inc., Natick, MA). The nondisplaceable binding potential (BPND) was then estimated: BPND = DVR-1. BPND
and R1, k2 values were also obtained from the SRTM
model (Lammertsma and Hume 1996; Watabe et al.
1996).
We also calculated the area under the time–activity
curve (AUC) for the striatal to cerebellar ratio (AUCstriatum/AUC-cerebellum); this is a simple model and
input function-independent method to quantify an index
of tracer accumulation in the brain (Muller Herde et al.
2015). The 60–120 min data were used for AUC ratio calculation, since the striatum-to-cerebellum SUV ratio
reaches a plateau at this time point. Ideally, the AUC
ratio equals the DVR determined by LoganREF model
(Muller Herde et al. 2015). Thus, bias was calculated as
(mean AUC ratio - mean DVR)/mean AUC ratio (Choi
et al. 2015).

Comparison of PDE10A PET Tracer [11C] TZ1964B and [18F] MNI659

organic layer and 1 mL of the aqueous layer were separated and loaded in a gamma counter. The results were
corrected for background radiation and physical decay.
The partition coefficient Log D7.4, which equals Log P,
was calculated as the decimal logarithm the ratio of cpm/
mL of 1-octanol to that of PBS.

Statistical analysis
BPND, AUC ratio, and other kinetic parameters of radiotracers were expressed as mean  standard deviation
(SD). Pearson’s correlation was performed to determine
the relationship between BPND and AUC ratio. The
reported data represented the results of all four double
scan experiments. All statistical analysis was processed by
Graph Prism 5 (GraphPad Software Inc., San Diego, CA).

Results
Radiosynthesis

Metabolite studies
The radiometabolite analysis was performed according to
previous reports (Tu et al. 2011, 2015). Arterial blood
samples (1.2–1.5 mL) were collected in a heparinized syringe at 2, 5, 15, 30, and 60 min (for [11C]TZ1964B) or 5,
15 30, 60, 90, and 120 min (for [18F]MNI659) postinjection of each radiotracer. Plasma (400 lL) was collected
by centrifugation of the whole blood and mixed with icecold methanol (0.92 mL) to deproteinate and extract the
parent compound and radiolabeled metabolites. After
centrifugation, the supernatant was mixed with water
(1/1, v/v), and loaded onto a HPLC system with an Agilent SB C-18 analytical HPLC column (250 mm 9
4.6 mm, 5 l) and a UV detector with 254 nm wavelength. The mobile phase was acetonitrile/0.1 mol/L
ammonium formate buffer pH 4.5, (52/48, v/v) with a
flow rate of 1.0 mL/min. The eluted fractions were collected for 16 min at 1 min intervals; the radioactivity of
in each fraction was counted in a well counter, and
results were corrected for background radiation and
physical decay.

Log P Measurement
Log P was measured according to the previous report (Li
et al. 2013b), by adding different volumes of [11C]
TZ1964B or [18F]MNI659 into a mixture of 1-octanol
(3 mL) and 0.1 mol/L phosphate-buffered saline (PBS,
pH 7.4, 3 mL). The mixture was vortexed and then centrifuged. Then, 2 mL organic layer was mixed with 1 mL
1-octanol and 3 mL PBS buffer. The resulting mixture
was vortexed and centrifuged again. Then 1 mL of the

[11C]TZ1964B was obtained in high specific activity >296
GBq/mol (decay corrected to end of bombardment), with
radiochemical yield 20–30% (decay corrected to end of
bombardment) and radiochemical purity >99%. [18F]
MNI659 was obtained in high specific activity 37-74 GBq/
lmol (decay corrected to end of bombardment), with
radiochemical yield 20–30% (decay corrected to end of
bombardment) and radiochemical purity >99%.

Comparison of regional brain uptakes
Both radiotracers showed high accumulation in NHP
striatum (Fig. 3). The regional tracer uptake pattern in
the NHP brain was identical for these two radioligands:
striatum had highest uptake, followed by midbrain; frontal cortex, hippocampus, and cerebellum, which showed
low level of tracer accumulation. (Table 1 and 2). Striatal
and cerebellar peak SUV values for [18F]MNI659 PET
were higher than those of [11C]TZ1964B PET (Fig. 4). In
[11C]TZ1964B PET, striatal uptake reached the max SUV
value ~40–60 min p.i. and declined slowly (Fig. 4A). In
[18F]MNI659 PET, the peak appeared at about 10 min
p.i., and declined rapidly (Fig. 4B).

Comparison of regional binding values and
kinetic parameters
BPND, AUC ratio, and kinetic parameters are summarized
in Figure 5 and Table 1 and 2. The striatal BPND and
AUC ratio values of [18F]MNI659 PET were higher than
the corresponding values for [11C]TZ1964B PET, however, the difference was not statistically significant due to
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Figure 3. Representative PET images of [11C]TZ1964B and [18F]MNI659 in NHP brains. Both radiotracers showed high accumulation in NHP
striatum (red/yellow areas).

Table 1. Binding potential, AUC ratio, and kinetic parameters for
[11C]TZ1964B and [18F]MNI659 in NHP striatum1.
[11C]TZ1964B
AUC ratio (Stri/Cere)
BPND-Logan
BPND-Logan CV (%)
Bias (DVR v.s. AUC ratio)2
BPND-SRTM
BPND-SRTM CV (%)
R1
k2 (min 1)

5.87
3.72
16.61
0.20
4.39
8.77
1.16
0.13

 0.45
 0.62

 0.39
 0.17
 0.017

[18F]MNI659
7.60
5.08
31.93
0.20
5.33
25.5
1.20
0.28

 2.68
 1.62

 1.36
 0.20
 0.13

n = 4 scans in 2 NHPs. Data were presented as mean  SD.
DVR = BPND-Logan + 1. Bias was calculated as (mean AUC ratio mean DVR)/mean AUC ratio.

1

Analysis of radiolabeled metabolites in plasma extracts of
[11C]TZ1964B after 60 min p.i. was hampered due to low
radioactivity in the plasma at later time points. HPLC
radiometabolite analysis revealed [11C]TZ1964B was more
stable than [18F]MNI659 in vivo. At 60 min, the percentage of parent compounds were ~70% and ~50%, for [11C]
TZ1964B and [18F]MNI659, respectively.
The measured Log P values were 1.98  0.09, and
1.98  0.06, for [11C]TZ1964B and [18F]MNI659,
respectively.

Discussion

2

large variation of [18F]MNI659 PET values. Notably, [18F]
MNI659 displayed a higher striatal K2 value (twofold)
than [11C]TZ1964B. For other ROIs, [18F]MNI659 had
lower cerebellar uptake, determined by AUC, than [11C]
TZ1964B, and midbrain showed modest uptake of both
tracers. The correlations between the AUC ratio values
and DVR values were strong and positive for both radiotracers (R2 = ~0.97, Fig. 6). However, compared to DVR
values, the AUC ratio values were mostly overestimated.
Brain regions with high PDE10A-expression appeared to
have higher overestimation than regions with lower
PDE10A density. The overestimation of AUC ratio and
DVR was similar for both tracers. Strong correlation
between BPND values (either BPND-Logan or BPNDSRTM) and AUC ratio values, was also observed for both
[11C]TZ1964B and [18F]MNI659 (Fig. 7).

Comparison of tracer metabolism and Log P
The fraction of parent radioligand and corresponding
radiolabeled metabolites in plasma are shown in Figure 8.
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In this study, the binding of two potent and selective
PDE10A radioligands, [11C]TZ1964B and [18F]MNI659,
was examined and compared in the NHP brain using several quantitative approaches. For an ideal brain PET
radiotracer, there are several generally required properties,
including small molecular weight, appropriate lipophilicity, high binding affinity, good target selectivity, favorable
in vivo kinetics, and metabolism (Fumita and Robert
2000). In this case, molecular weights of both TZ1964B
and MNI659 are under 600 Daltons. Moreover, both
ligands have similar lipophilicity (measured Log P values
equal 1.98 for both ligands), as well as subnanomolar
in vitro binding affinity, although the reported binding
affinity of MNI659 is higher than that of TZ1964B.
According to the crystal structure of PDE10A (Chappie
et al. 2012), TZ1964B binds to two key sites in the selectivity pocket, which are the selectivity pocket (S) and the
hydrophobic clamp (H). MNI659 and its analogs binds
with four key elements of the selectivity pocket, including
S, H, the Gln interaction (G), and the exo-binding site
(E); this may result in the observed increased binding
affinity to PDE10A compared with TZ1964B.
Although both tracers are able to map PDE10A in the
NHP brain, their in vivo binding measures and tracer
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Table 2. BPND and AUC ratio values for [11C]TZ1964B and [18F]MNI659 in other brain regions1.
[11C]TZ1964B

[18F]MNI659

Regions

AUC ratio

BPND-Logan

BPND-SRTM

AUC ratio

BPND-Logan

BPND-SRTM

Midbrain
Frontal cortex
Hippocampus

1.51  0.47
1.38  0.13
1.35  0.41

0.26  0.20
0.15  0.05
0.11  0.25

0.57  0.30
0.43  0.28
0.32  0.50

2.59  0.42
1.37  0.12
1.08  0.23

1.02  0.14
0.29  0.10
0.11  0.18

1.11  0.16
0.29  0.09
0.16  0.20

n = 4 scans in 2 NHPs. Data were presented as mean  SD.

1

Figure 4. Averaged SUV curves of [11C]TZ1964B and [18F]MNI659 in the striatum and the cerebellum of NHP brains (n = 4 scans in 2 NHPs).
Dark lines indicated moving average (Mov. Avg.) trendlines. SUV, standardized uptake value.

kinetics are not identical. Using either reference-based
LoganREF method or modeling-independent AUC ratio
method, [18F]MNI659 showed higher striatal binding
affinity than [11C]TZ1964B, which agreed with the
in vitro binding data. Due to differences in plasma clearance (fast) and tissue clearance (slow), the apparent DVR
values and AUC ratios are larger than the total DVR values and AUC ratios obtained from kinetic modeling,
which produces overestimation (Choi et al. 2015). Interestingly, the overestimation of [11C]TZ1964B and [18F]
MNI659 in the striatum are exactly the same (0.20)
(Table 1). As a result, this overestimation produces low
accuracy of AUC tissue to reference ratio methods hampers its application to BPND estimates for both [11C]
TZ1964B and [18F]MNI659, regardless of the good correlation between AUC ratio and DVR for both tracers.
Notably, the variation of BPND and AUC ratio data of
[18F]MNI659 is large, which has also been reported in
human brain imaging (Barret et al. 2014). In contrast,

[11C]TZ1964B has less variance in BPND calculations in
NHP brain, which could translate to improved accuracy if
confirmed in humans. In addition, SRTM was also used
for the kinetics analysis in this study. The striatal BPND
values calculated by SRTM were higher than LoganREF
model, while the resulting striatal CV by SRTM was smaller than LoganREF model. Moreover, the correlation of
BPND-SRTM values between [11C]TZ1964B and [18F]
MNI659 was better than that of BPND-Logan and AUC
ratio. As noted previously (Barret et al. 2014; Liu et al.
2015), SRTM could be an appropriate modeling method
for in vivo quantification of PDE10A using either [11C]
TZ1964B or [18F]MNI659.
For in vivo tracer kinetics, [11C]TZ1964B had higher
striatal retention and relatively slower striatal washout
kinetics although the washout from the reference cerebellar region was rapid. Although high potency ligand binding to PDE10A may contribute to slower washout kinetics
in some cases (Hirvonen et al. 2010), for this two-tracer
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Figure 5. Binding potentials and AUC values (60-120 min) of striatum and cerebellum of [11C]TZ1964B and [18F]MNI659 in NHP brains (n = 4
scans in 2 NHPs). BPND-SRTM, binding potential estimated by SRTM modeling; BPND-Logan, binding potential estimated by Logan modeling; AUC,
area under the time–activity curve.

Figure 6. Relationship between the DVR and AUC ratio values for [11C]TZ1964B and [18F]MNI659 in NHP brains (n = 4 scans in 2 NHPs, 4 brain
regions included). The AUC ratio values of both tracers strongly correlated with DVR values.
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Figure 7. Correlation of BPND and AUC ratio values between [11C]TZ1964B and [18F]MNI659 in NHP brains (n = 4 scans in 2 NHPs, 4 brain
regions included) Strong correlation of BPND values (either BPND-Logan or BPND-SRTM), as well as AUC ratio values, was observed between [11C]
TZ1964B and [18F]MNI659.

Figure 8. Percent radioactivity in NHP plasma of [11C]TZ1964B, [18F]MNI659 and the corresponding metabolites (n = 1). At 60 min, the
percentage of parent compounds were ~70% and ~50%, for [11C]TZ1964B and [18F]MNI659, respectively.

comparison study, there is no change in the PDE10A
density of the animal for each double scan. The binding
affinity of [11C]TZ1964B to PDE10A is comparable to
[18F]MNI659. These two factors (radioligand binding
affinity and target density) would not explain the slower
striatal washout kinetics of [11C]TZ1964B in this study.

One explanation is that the k2 value, obtained by SRTM
modeling, was smaller for [11C]TZ1964B than [18F]
MNI659, thus the efflux rate constant (across the blood–
brain barrier) (Liu et al. 2015) for [11C]TZ1964B was
slower than [18F]MNI659. Another possible reason may
be increased metabolic stability. [11C]TZ1964B was more
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stable than [18F]MNI659 in vivo, which may result in a
higher concentration in the brain and higher striatal
retention of [11C]TZ1964B, compared with [18F]MNI659
at the same time point p.i. Nevertheless, the peak striatal
uptake time of [11C]TZ1964B is 55–60 min p.i. (Fig. 4A)
which is acceptable for clinical use. The higher striatal
retention suggest more stable binding of [11C]TZ1964B to
striatal PDE10A, which may improve reproducibility of
the PET measurement at later times such as 60 min p.i.
Notably, the pattern of [11C]TZ1964B SUV curve in
NHP striatum shown in Figure 4A is slightly different
from our previous report (Liu et al. 2015). The SUV
curve published previously represented one scan from a
single animal. This study included data from four scans
in two NHPs. Although there was good reproducibility
between the two subjects here, between-subject variation
could account for the difference in the shape of the SUV
curve from the earlier report. Despite that observation,
BPND estimates by reference modeling methods in the
two studies were similar, supporting reliable reproducibility of [11C]TZ1964B PET imaging.
In conclusion, despite differences in in vivo tracer characteristics, both [11C]TZ1964B and [18F]MNI659 could
serve as a suitable PET radiotracer for assessment of brain
PDE10A level and for measuring target engagement for
new therapeutic interventions. Due to the half-life of
radioisotopes, the 11C-labeled tracer could be utilized for
repeated or multiple scans in the same subject on the
same day, while the 18F-labeled tracer could be used for
several sequential PET studies in different subjects and
would permit delivery of the radioligand to off-site imaging facilities within 3 h travel time. [11C]TZ1964B has
higher striatal retention, so it could provide better measurements for static scan acquisition, for steady-state analysis methods, or for displacement studies. [18F]MNI659
shows higher initial tracer uptake, and could be preferred
for short-term dynamic scans or for measurement of dissociation rates. The results of this comparison study of
two PDE10A radiotracers are based on a limited sample
size of NHPs, the consistent performance of both tracers
gives promise for assessing PDE10A in vivo. Increasing
sample size of NHPs and further characterizing these two
tracers in human subjects is warranted for selecting the
ideal tracer for particular clinical applications.
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